|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2010-12-17
|
|
pubmed:abstractText |
We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors for the achievement of complete cytogenetic responses on third-line therapy. Younger age and the achievement of a cytogenetic response on second line were the only independent predictors for overall survival (OS). At 3 months, the 9 patients who had achieved a cytogenetic response had better 30-month probabilities of complete cytogenetic responses and OS than the patients who had failed to do so. Factors measurable before starting treatment with third line therapy and cytogenetic responses at 3 months can accurately predict subsequent outcome and thus guide clinical decisions.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:ApperleyJane FJF,
pubmed-author:BuaMarcoM,
pubmed-author:DazziFrancescoF,
pubmed-author:ForoniLetiziaL,
pubmed-author:GoldmanJohn MJM,
pubmed-author:IbrahimAmr RAR,
pubmed-author:KhorashadJamshid SJS,
pubmed-author:MarinDavidD,
pubmed-author:MilojkovicDraganaD,
pubmed-author:PaliompeisChristosC,
pubmed-author:ReidAlistairA,
pubmed-author:RezvaniKatayounK,
pubmed-author:SzydloRichardR,
pubmed-author:de LavalladeHuguesH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
16
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5497-500
|
|
pubmed:meshHeading |
pubmed-meshheading:20833982-Age Factors,
pubmed-meshheading:20833982-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20833982-Cohort Studies,
pubmed-meshheading:20833982-Drug Resistance, Neoplasm,
pubmed-meshheading:20833982-Female,
pubmed-meshheading:20833982-Follow-Up Studies,
pubmed-meshheading:20833982-Humans,
pubmed-meshheading:20833982-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:20833982-Male,
pubmed-meshheading:20833982-Middle Aged,
pubmed-meshheading:20833982-Piperazines,
pubmed-meshheading:20833982-Protein Kinase Inhibitors,
pubmed-meshheading:20833982-Pyrimidines,
pubmed-meshheading:20833982-Remission Induction,
pubmed-meshheading:20833982-Salvage Therapy,
pubmed-meshheading:20833982-Thiazoles,
pubmed-meshheading:20833982-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
|
|
pubmed:affiliation |
Department of Haematology, Imperial College London, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
